| scholarly article | Q13442814 |
| P50 | author | Tobias Fechter | Q55441647 |
| P2093 | author name string | Florian Schiller | |
| Martin Werner | |||
| Alin Chirindel | |||
| Vanessa Drendel | |||
| Michael Mix | |||
| Anca Ligia Grosu | |||
| Cordula Annette Jilg | |||
| Gesche Wieser | |||
| Constantinos Zamboglou | |||
| Philipp Tobias Meyer | |||
| Nasr Salman | |||
| P2860 | cites work | Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy | Q56969116 |
| Accuracy of Multiparametric MRI for Prostate Cancer Detection: A Meta-Analysis | Q57253236 | ||
| Clinically Significant Prostate Cancer Local Recurrence After Radiation Therapy Occurs at the Site of Primary Tumor: Magnetic Resonance Imaging and Step-Section Pathology Evidence | Q57392756 | ||
| Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy | Q60606969 | ||
| Assessment of outcome prediction models for localized prostate cancer in patients managed with external beam radiation therapy | Q77312927 | ||
| Prostate-specific membrane antigen expression in normal and malignant human tissues | Q77553386 | ||
| Histopathological correlation of (11)C-choline PET scans for target volume definition in radical prostate radiotherapy | Q84159554 | ||
| Advancements in MR imaging of the prostate: from diagnosis to interventions | Q24594047 | ||
| Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation | Q33746637 | ||
| The role of focal therapy in the management of localised prostate cancer: a systematic review | Q34266167 | ||
| Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. | Q35777339 | ||
| Use of patient-specific MRI-based prostate mold for validation of multiparametric MRI in localization of prostate cancer | Q36501542 | ||
| Registration methodology for histological sections and in vivo imaging of human prostate | Q37105128 | ||
| Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy | Q37175207 | ||
| A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score | Q37213040 | ||
| Preliminary experience with a novel method of three-dimensional co-registration of prostate cancer digital histology and in vivo multiparametric MRI. | Q37447030 | ||
| Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription | Q37847721 | ||
| Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy | Q37864722 | ||
| The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis | Q38102842 | ||
| Boosting imaging defined dominant prostatic tumors: a systematic review | Q38116213 | ||
| EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. | Q38160994 | ||
| Dynamic contrast-enhanced MRI for the detection of prostate cancer: meta-analysis. | Q38385402 | ||
| Simultaneous (68)Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. | Q40959799 | ||
| Comparative study with new accuracy metrics for target volume contouring in PET image guided radiation therapy. | Q41513145 | ||
| Tracking the clonal origin of lethal prostate cancer | Q41762568 | ||
| Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy | Q42555504 | ||
| ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer | Q43156292 | ||
| Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer | Q43493056 | ||
| 11C-Choline PET/pathology image coregistration in primary localized prostate cancer | Q45797636 | ||
| Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis | Q46735738 | ||
| Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. | Q46925555 | ||
| Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens. | Q51262657 | ||
| The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. | Q51578822 | ||
| Influence of Statistical Fluctuation on Reproducibility and Accuracy of SUVmax and SUVpeak: A Phantom Study. | Q51810120 | ||
| MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. | Q52988044 | ||
| Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. | Q53000430 | ||
| Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. | Q53023502 | ||
| Correlation of Intraprostatic Tumor Extent with ⁶⁸Ga-PSMA Distribution in Patients with Prostate Cancer. | Q53208631 | ||
| The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. | Q53467850 | ||
| [3D volume and SUV analysis of oncological PET studies: a voxel-based image processing tool with NSCLC as example] | Q53469099 | ||
| (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? | Q53505313 | ||
| Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. | Q53572699 | ||
| P433 | issue | 10 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 1619-1628 | |
| P577 | publication date | 2016-06-18 | |
| P1433 | published in | Theranostics | Q21051383 |
| P1476 | title | (68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison | |
| P478 | volume | 6 |
| Q47693515 | (68) Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature. |
| Q92423926 | 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging |
| Q89848845 | 68Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study |
| Q51749167 | 68Ga-PSMA-PET/CT imaging of localized primary prostate cancer patients for intensity modulated radiation therapy treatment planning with integrated boost. |
| Q49713199 | Advances in prostate-specific membrane antigen PET of prostate cancer |
| Q37541876 | Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology |
| Q41436127 | Comparison of PET/CT and whole-mount histopathology sections of the human prostate: a new strategy for voxel-wise evaluation. |
| Q89638529 | Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity |
| Q42257970 | Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer |
| Q55317289 | Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference. |
| Q50112903 | Future Perspectives and Challenges of Prostate MR Imaging |
| Q57107850 | Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer |
| Q96128360 | Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11-PET |
| Q59130960 | Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents |
| Q38641232 | Multimodality Image Fusion with PSMA PET/CT and High-Intensity Focused Ultrasound Focal Therapy for Primary Diagnosis and Management of Prostate Cancer: A Planned Research Initiative |
| Q39407794 | PSMA ligands in prostate cancer - Probe optimization and theranostic applications |
| Q55399763 | PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. |
| Q50182743 | Performance of 68Ga-PSMA PET/CT for Prostate Cancer Management at Initial Staging and Time of Biochemical Recurrence |
| Q52589267 | Potential impact of 68Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning. |
| Q64265749 | Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference |
| Q50034009 | Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer |
| Q54943221 | Salvage high-dose-rate brachytherapy for prostate cancer persistence after brachytherapy: repeated use of a polyethylene glycol hydrogel spacer. |
| Q55077981 | The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer. |
Search more.